Effect of topical 0.05% cyclosporine A on the tear protein lacritin in a rat model of dry eye

Fen-Dui Zhang¹, Zhao-Qin Hao², Wei Gao², Yi-Qiao Xing¹

¹Eye Center, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China
²Department of Ophthalmology, Xi’an No.1 Hospital, Xi’an 710002, Shaanxi Province, China

Correspondence to: Yi-Qiao Xing. Eye Center, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China. yiqiao_xing57@whu.edu.cn

Received: 2018-08-27    Accepted: 2018-12-12

Abstract
● AIM: To observe the effect of topical 0.05% cyclosporine A (CsA) on the ocular surface and tear protein lacritin in a botulinum B-induced dry eye rat model.
● METHODS: A total of 36 female SD rats were randomly divided into 3 groups, botulinum B was injected into the right lacrimal gland of all rats. Group A and group B were treated with 0.05% CsA and 0.1% sodium hyaluronate, respectively, 3 times daily. The control group was not treated. Basal tear flow, corneal epithelial defects, and lacritin levels were measured.
● RESULTS: Tear secretion in all rats was reduced on day 3 and was even lower on day 7 postoperation (P<0.05). Tear secretion in group A increased by day 14 and was at the preoperative level on day 42. Tear secretion in group B and control rats was lower on days 14 and 42 compared with preoperative level (P<0.05). Corneal fluorescein staining in group A was higher on day 3, peaked on day 7, and then decreased gradually from day 7 until day 14, returning to normal by day 42 post-procedure. However, in group B, corneal fluorescein staining had improved, but was not fully recovered by day 42. Corneal fluorescein staining was more intense than before the operation and then in the control group at all time points. Tear protein lacritin levels reached the lowest levels on day 7 in all groups. In group A, tear protein lacritin levels began to increase on day 14 and were normal on day 42. In group B, tear protein lacritin levels began to increase on day 14, but had not completely recovered on day 42. In the control group, tear protein lacritin levels remained low post-procedure.
● CONCLUSION: CsA 0.05% prompts tear protein lacritin expression in a rat model of dry eye and improves the signs and symptoms of dry eye disease.

KEYWORDS: 0.05% cyclosporine A; tear protein lacritin; dry eye
DOI:10.18240/ijo.2019.02.01

Citation: Zhang FD, Hao ZQ, Gao W, Xing YQ. Effect of topical 0.05% cyclosporine A on the tear protein lacritin in a rat model of dry eye. Int J Ophthalmol 2019;12(2):189-193

INTRODUCTION
Dry eye is a multifactorial disease of the tear and ocular surface. Which causes discomfort, visual disturbances, and can even result in anxiety and irritability. Dry eye can affect people’s lives and work efficiencies, even in mild cases not caused by organic disease. Moderate and severe cases of dry eye may result in corneal neovascularization, damage to the ocular surface, and ultimately irreversible vision loss. Dry eye has garnered more attention recently and treatments for dry eye have been proposed. Immunosuppressants are capable of stimulating tear production and may be a new option for dry eye treatment. They have been found to be effective in very severe cases of dry eye, however the mechanism by which immunosuppressants stimulate tear production remains unclear. The purpose of this study was to observe the effect of topical 0.05% cyclosporine A (CsA) on the ocular surface and tear protein lacritin in a botulinum B-induced rat model of dry eye and to provide an experimental basis for treating dry eye with 0.05% CsA.

MATERIALS AND METHODS
Ethical Approval    We confirmed adherence to the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in this study and received approval from Wuhan University Institutional Animal Use and Care Committee.

A total of 36 female SD rats (8wk, 200-250 g), with normal eyes and no ocular pathologies, were randomly divided into 3 groups as follows: group A (n=15), group B (n=15) and a control group (n=6). Botulinum B was injected into the right lacrimal gland of all rats. Botulinum B for injection was obtained from Elan (USA). Tear test strips were purchased from Tianjin Jingming New Technology Development Co., Ltd. (China). Anti-rat tumor necrosis factor (TNF)-α monoclonal antibody was purchased from Zhongshan Jinqiao Biotechnology Co., Ltd. (China). Goat anti-rat interleukin
(IL)-6 monoclonal antibody was received from Pepro Tech (USA). Anti-rat lacritin protein antibody was obtained from Santa Cruz (USA). Tear protein lacritin expression were observed using photographic slit microscopy (SL-1E Topcon, Japan). Tear protein lacritin levels were detected using fluorescence microscopy (BX51 Olympus, Japan).

Methods Animals were anesthetized via intraperitoneal injection of 10% chloral hydrate (4 mL/Kg). The right lacrimal gland of each rat was exposed under a surgical microscope and injected with 0.1 mL (20 milliunits, mU) of botulinum-B. Animals were fed a regular diet. The animals had free access to food and water and they were on a 12h light/dark cycle. Group A rats were treated with 0.05% CsA eye drops three times daily and group B were treated with 0.1% sodium hyaluronate eye drops three times daily, beginning three days after injection. Control group rats were not treated.

Rats were sedated using basic anesthesia and basal tear flow was measured with Schirmer strips on days 1, 3, 7, 14, and 42 post-injection. The Shirmer strip was placed inside the lower eyelid for 5min, taking care to avoid corneal stimulation, and the amount of wetting was measured in millimeters.

Corneal fluorescein staining was evaluated 1min after fluorescein instillation using a slit lamp with a cobalt blue light. Corneal staining was scored from 0 to 4 as follows: 0) no fluorescein stain; 1) ≤1/8 of corneal surface stained; 2) ≤1/4 of corneal surface stained; 3) ≤1/2 of corneal surface stained; 4) >1/2 of corneal surface stained.

Rats were randomly euthanized at 3, 7, 28, and 42d post-procedure (specific numbers of rats from each group). The lacrimal glands were immediately removed and fixed in 4% paraformaldehyde for 24h. The lacrimal glands were then paraffin-embedded, sectioned and immunohistochemically stained, followed the instructions. Rabbit anti-lacritin (Santa Cruz), diluted 1:50 in PBS-T; mouse nestin (Chemicon), diluted 1:200 in PBS-T; mouse GFAP (Chemicon), diluted 1:50 in PBS-T; goat DCX (Santa Cruz), diluted 1:100 in PBS-T; mouse NeuN (Chemicon), diluted 1:300 in PBS-T; and mouse IL-6 monoclonal antibody was received from Pepro Tech, USA) diluted 1:2000 in PBS-T for 2h at room temperature, incubated with anti-rat lacritin protein antibody, diluted 1:300 in the blocking solution, overnight at room temperature, rinsed with PBS-T (3×10min), and incubated with goat anti-rat IL-6 monoclonal antibody (PeproTech, USA) diluted 1:2000 in PBS-T for 2h at room temperature. Blots were blocked for 1h at room temperature, incubated with anti-rat lacritin protein antibody, diluted 1:300 in the blocking solution, overnight at room temperature, rinsed with PBS-T (3×10min), and incubated with goat anti-rat IL-6 monoclonal antibody (PeproTech, USA) diluted 1:2000 in PBS-T for 2h at room temperature. Blots were rinsed with PBS-T (3×10min) and developed via chemiluminescence using Western blotting substrate. The experiment was repeated 3 times and β-actin was used as an internal reference. The results of the Western blot were analyzed using the Gene Tools software of UK Syn gene.

Statistical Analysis Data are expressed as mean±standard deviation. Variance analysis of multiple comparisons between multiple samples was used for each group. Corneal fluorescence staining was analyzed via the Mann-Whitney method using SPSS 16.0 (USA). P<0.05 was considered statistically significant.

RESULTS Tear secretion in all rats was significantly reduced on days 3 and 7 compared with preoperative levels (P<0.05). Tear secretion increased in group A on day 14 and had recovered to the preoperative level on day 42. Tear secretion was lower in group B and control rats on days 14 and 42 compared to preoperative levels (P<0.05; Table 1).
Corneal fluorescein staining was positive in all groups on day 3. Corneal fluorescein staining in group A increased after beginning eye drops, worsening from a spot to a sheet on day 7, but gradually improved by day 14 and was fully recovered on day 42. Corneal fluorescein staining improved in group B, but was not fully recovered on day 42. Corneal fluorescein staining in control group rats slowly enlarged to a sheet and was worse compared with group A and group B rats on days 7, 14 and 42 (Table 2).

Tear protein lacritin expression was mainly restricted to lacrimal acinar cells, and was not detected in other lacrimal gland tissues or duct sections (Figure 1).

Tear protein lacritin levels began to decrease on day 3 and reached the lowest level on day 7 in all groups. In group A, tear protein lacritin increased on day 14 and had recovered on day 42, however tear protein lacritin did not fully recover in group B. Tear protein lacritin level was lower than pre-procedure levels in the control group at all time points (Figure 2).

DISCUSSION

Dry eye is one of the most common ocular surface diseases. The lacrimal functional unit (LFU) is defined as an integrated system that is comprised of tear film, lacrimal glands, corneal and conjunctival epithelium, meibomian glands, lids, and the sensory and motor nerves that connect them[1]. The LFU plays a vital role in maintaining a healthy ocular surface[2]. Dry eye is a complex multifactorial disease associated with inflammation, tear film instability, tear hyperosmolarity, changes in sex hormones[3], and dysfunction of the nervous system. It is characterized by symptoms of ocular surface discomfort and irritation. Although the causes for dry eye are various[4-6], inflammation is the most critical factor in the pathogenesis and progression of dry eye[7-8]. Furthermore, inflammation involves every component of the LFU[9-10]. Immune-related inflammation is attributed to lymphocytic infiltration of the lacrimal and ocular surface tissue and the release of inflammatory factors. Inflammatory factors damage the neuromodulation of tear secretion, subsequently affecting the quality and quantity of tears, which ultimately becomes a malignant cycle[11]. Thus, a chronic pseudo-immune rat model of dry eye, similar to that observed in humans, was established in the current study as an approach to treating the inflammation associated with dry eye.

Botulinum-B blocked the neuromuscular and cholinergic connections of the sweat glands and lacrimal glands, and inhibited tear and sweat secretion. The chronic pseudo-immune rat model of dry eye in this study reflected the pathological mechanism of dry eyes in humans. Corneal fluorescence staining was persistent in group B rats, which were treated

<table>
<thead>
<tr>
<th>Table 1 Tear secretion in each group</th>
<th>mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group Preop. 3d postop. 7d postop. 14d postop. 42d postop.</td>
<td></td>
</tr>
<tr>
<td>Control 5.01±0.25 2.04±0.72 2.01±0.42 3.01±0.78 2.00±0.21</td>
<td></td>
</tr>
<tr>
<td>Group A 5.02±0.35 2.46±0.28 3.01±0.78 4.84±0.46</td>
<td></td>
</tr>
<tr>
<td>Group B 5.12±0.43 2.21±0.45 3.02±0.12 2.97±0.54 2.86±0.41</td>
<td></td>
</tr>
</tbody>
</table>

| Table 2 Comparison of corneal staining of groups |
|----------------|---|
| Group Preop. 3d postop. 7d postop. 14d postop. 42d postop. |
| Control 0.01±0.23 1.04±0.42 2.41±0.95 2.54±0.54 3.05±0.26 |
| Group A 0.02±0.32 1.35±0.72 2.01±0.86 1.41±0.78 0.04±0.46 |
| Group B 0.01±0.33 1.12±0.76 1.04±0.42 2.47±0.37 1.06±0.42 |

$^aP<0.05$ vs preoperative.
with artificial tears and no anti-inflammatories. This suggests that inflammation has always existed in dry eye since the tear secretion was normal in group B rats. Previous studies have shown that, unlike in humans, there is no difference in the effects of botulinum-A and botulinum-B in rats\(^{[15]}.\) botulinum-B has a more extensive target and causes a more rapid response, thus botulinum-B was chosen to develop the rat model of dry eye used in this study.

All rats showed signs of dry eye on day 3, such as decreased tear secretion and corneal epithelial defects. These signs were persistent for 6-8 wk, even though tear secretion had recovered. Corneal epithelial defects were still present on day 42. No corneal necrosis or ulceration was observed in any subject during the course of the study.

Earlier experiments have confirmed that the levels of ocular surface inflammatory factors, such as IL-1β, TNF-α, and macrophage migration inhibitory factor are increased in the rat model of dry eye\(^{[12]}\). Although it is still not clear what proteins make up the human tear proteome, over 400 proteins have been reported. It is thought that no more than 5% of these participate in ocular surface disease, of which lacritin is the only one apparently capable of promoting tear production\(^{[13]}\). Lacritin is wide-spread in the LFU and is an important component of tears\(^{[14]}\). In addition, it has been found that lacritin, as a growth factor protein, plays an important role in the occurrence and development of dry eye\(^{[15-16]}\), though the mechanism for this is still not clear.

Lacritin is mainly secreted by the lacrimal gland and flows through ducts to target corneal epithelial cells\(^{[17]}\). Lacritin promotes mitosis, corneal epithelial cell proliferation, and tear secretion\(^{[18]}\). In dry eyes, lacritin is decreased due to the effects of inflammatory factor IL-2, particularly in cases of severe dry eye\(^{[19-22]}\). Therefore, the current study lacritin was chosen as the target to investigate the efficacy of topical 0.05% CsA for the treatment of ocular surface inflammation. Lacritin had increased on day 14 and recovered by day 42 in rats treated with topical 0.05% CsA. However, lacritin had still not returned to normal on day 42 in rats treated with 0.1% sodium hyaluronate. The results of this study, suggest that 0.05% CsA inhibited the production of IL-2 in cells and subsequently blocked T-cell proliferation. Cyclosporine can inhibit T-cell-induced immune responses by selectively inhibiting the proliferation of T cells\(^{[23-24]}\), thus increasing lacritin levels in the dry eye rat model. Lacritin also promotes corneal wound healing and tear secretion\(^{[25]}\). In this study lacritin had decreased in the control group on day 3 and remained at a low level for 6 wk. This coincided with the decrease in tear secretion and damage to the ocular surface confirming that the level of lacritin is linked to tear secretion, ocular surface damage and dry eye severity.

In the current study, the lacrimal gland tissue structure remained intact and no T cell infiltration was found in pathological sections. This indicates that the lacritin was secreted by lacrimal acinar cells flowed through ducts to the ocular surface. Lacritin is mainly secreted by the lacrimal gland and meibomian gland with a small amount secreted by the cornea. The detection of lacritin in tear or conjunctiva can be used as an objective index to reflect lacrimal function and also as a measure of drug efficacy and/or complications.

Larger trials are needed to study the association between lacritin protein and inflammatory factors as well as the specific function and mechanisms of action of lacritin. In summary, in this study 0.05% CsA improved ocular surface repair and micro-environment by reducing the production of inflammatory cytokines. Lacritin in tears can be used as a marker to assess the progression of dry eye and the efficacy of the drugs used to treat dry eye.

**ACKNOWLEDGEMENTS**

**Foundations:** Supported by Natural Science Foundation of Shaanxi Province (No.S2010JC376); Xi’an Science and Technology Program Funding Project [No.SF1022(1)].

**Conflicts of Interest:** Zhang FD, None; Hao ZQ, None; Gao W, None; Xing YQ, None.

**REFERENCES**


